Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment as the companies double down on ...

Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug.

This collaboration with Roche is a step change to realize this vision, while solidifying Zealand Pharma as a key player in the future management of obesity”. Teresa Graham, Chief Executive ...

“We are incredibly excited to launch this partnership, which represents a step change to realize Zealand Pharma’s vision of becoming a key player in the future management of obesity. Roche ticked all ...

Petrelintide/CT-388, amylin+GLP-1/GIP fixed-dose combination. Zealand Pharma and Roche expect to initiate Phase 2 trials with petrelintide/CT-388 in the first half of 2026. Dapiglutide ...

Zealand Pharma A/S is a leading non-Big Pharma player in obesity drugs, with a promising pipeline and a major partnership with Roche for petrelintide. Petrelintide, an amylin analog, could rival ...

Zealand Pharma’s financial position has been significantly strengthened by the Roche partnership. As of March 2025, the company reported a cash position of DKK 8,544 million. Including the DKK 9,200 ...

European shares kicked off the week on a positive note on Monday, recouping the previous session's losses, as markets heaved a sigh of relief after U.S. President Donald Trump delayed his threat ...

COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss ...

“We are incredibly excited to launch this partnership, which represents a step change to realize Zealand Pharma's vision of becoming a key player in the future management of obesity. Roche ...

Zealand Pharma’s financial position has been significantly strengthened by the Roche partnership. As of March 2025, the company reported a cash position of DKK 8,544 million.